Search Within

Gary Schwartz

Formats
  1. Journal Article (191)
  2. Meeting Abstract (190)
  3. Conference Paper (3)
  4. Book Section (1)
Groups
  1. Department of Medicine (215)
  2. Solid Tumor Oncology Division (205)
  3. Melanoma Disease Management Team (129)
  4. Center for Pancreatic Cancer Research (99)
  5. Gastrointestinal Oncology Service (99)
  6. GSK Faculty (91)

More Groups

People
  1. David Kelsen (79)
  2. Richard Carvajal (61)
  3. Manish Shah (41)
  4. Mark Dickson (40)
  5. Eileen O'Reilly (36)
  6. Monica Motwani (36)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (2)
  4. 2016 (3)
  5. 2015 (5)
  6. 2014 (23)

More Years

Publications
  1. Journal of Clinical Oncology (103)
  2. Cancer Research (42)
  3. Clinical Cancer Research (39)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (30)
  5. Annals of Oncology (12)
  6. Cancer (12)

More Publications

Publishers
  1. American Association for Cancer Research (121)
  2. American Society of Clinical Oncology (105)
  3. Elsevier Inc. (20)
  4. Springer (20)
  5. Oxford University Press (16)
  6. Wiley Blackwell (15)

More Publishers

Results (385)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, induces a unique mitotic effect and potentiates flavopiridol (F) induced apoptosis
    Meeting Abstract

    Cheema, H. S.; Motwani, M. V.; Schwartz, G. K.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
    Meeting Abstract

    Tse, A. N.; Solit, D.; Rosen, N.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)
    Meeting Abstract

    Shah, M. A.; Kortmansky, J.; Gonen, M.; Tse, A.; Lefkowitz, R.; Kelsen, D.; Colevas, D.; Winkelman, J.; Yi, S.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Response assessment parameters in esophageal cancer - Conventional and novel techniques
    Meeting Abstract

    Schwartz, L. H.; Colville, J. A. C.; Wang, L.; Hricak, H.; Ilson, D.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Flavopiridol inhibits soft tissue sarcoma growth with preferential sensitivity in a Cdk4 gene amplified subtype
    Meeting Abstract

    Sambol, E. B.; Kennealey, P. T.; Motwani, M.; Chen, J. H.; Cheema, H.; Leversha, M.; Schwartz, G. K.; Singer, S.
    Journal of the American College of Surgeons (2004)

    Fulltext@MSK | Save
  • A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
    Meeting Abstract

    Rathkopf, D.; Fornier, M.; Shah, M.; Kortmansky, J.; O'reilly, E.; King, A.; Winkelmann, J.; Kelsen, D. P.; Olsen, S.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • A novel Aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy
    Meeting Abstract

    Nair, J. S.; Tse, A.; Keen, N.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Flavopiridol potentiates effect of oxaliplatin in vitro and in vivo and requires intact p53
    Meeting Abstract

    Motwani, M. V.; Racanelli, A.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil
    Meeting Abstract

    Kortmansky, J. S.; Sauter, N.; O'reilly, E.; Shah, M.; Abou-Alfa, G. K.; Winkelmann, J.; Yi, S.; Gonen, M.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase I dose-finding study of weekly (W) docetaxel (T) followed by flavopiridol (F) for patients with metastatic solid tumors
    Meeting Abstract

    Fornier, M. N.; Rathkopf, D.; Shah, M.; Hudis, C.; O'reilly, E.; Kortmansky, J.; Winkelmann, J.; Kelsen, D.; Norton, L.; Schwartz, G. K.
    Annals of Oncology (2004)

    Fulltext@MSK | Save